Astellas Pharma — Urinary Autonomic Dysfunction

Astellas Pharma — Urinary Autonomic Dysfunction Focus

Company: Astellas Pharma Inc. Headquarters: Tokyo, Japan Founded: 2005 (merger of Yamanouchi and Fujisawa) Ticker: 4503 (TSE) Revenue: ~¥1.3 trillion (2024) Global Presence: 70+ countries

Overview

Astellas Pharma — Urinary Autonomic Dysfunction Focus

Company: Astellas Pharma Inc. Headquarters: Tokyo, Japan Founded: 2005 (merger of Yamanouchi and Fujisawa) Ticker: 4503 (TSE) Revenue: ~¥1.3 trillion (2024) Global Presence: 70+ countries

Overview

[Astellas Pharma](/companies/astellas-pharma) is a global pharmaceutical company with one of the largest urology portfolios in the industry, anchored by [Betimiga (mirabegron), marketed as Myrbetriq in the US](/therapeutics/mirabegron) — a beta-3 adrenergic receptor agonist for overactive bladder (OAB) and neurogenic bladder. The company's leadership in autonomic urology makes it a key player in addressing urinary dysfunction in [Parkinson's disease](/diseases/parkinsons-disease) and related neurodegenerative disorders["@astellas-urology"].

Urinary dysfunction affects 45-70% of PD patients, manifesting as overactive bladder (urgency, frequency, nocturia) due to detrusor overactivity from loss of dopaminergic inhibition in the basal ganglia circuits["@sakakibara-urology"]. Unlike anticholinergic agents that worsen cognition in elderly and neurodegenerative patients, mirabegron offers a cognitive-sparing alternative.

Betimiga/Myrbetriq (Mirabegron)

Mechanism of Action

Beta-3 Adrenergic Receptor Agonism:

Mirabegron selectively activates the beta-3 adrenergic receptor (beta3-AR) in the urinary bladder:

Pharmacology:

• Selective beta3-AR agonist (Ki ~ 19 nM at human beta3-AR)
• Minimal activity at beta1 or beta2 receptors (reduces cardiovascular effects)
• Oral bioavailability ~40-50%
• Half-life ~50 hours enabling once-daily dosing

PD-Specific Relevance

Patients with [Parkinson's disease](/diseases/parkinsons-disease) commonly develop overactive bladder (OAB) symptoms:

• Urinary urgency (most common, 60-70%)
• Frequency (50-60%)
• Nocturia (60-80%)
• Urge incontinence (30-40%)

| Risk Factor | Anticholinergics | Mirabegron |
|------------|-----------------|-------------|
| Cognitive impairment | High risk (crosses BBB) | Low risk (minimal BBB penetration) |
| Dementia progression | May accelerate | No significant signal |
| Dry mouth | High | Moderate |
| Constipation | High (already a problem in PD) | Low |
| Cardiac | QT prolongation risk | Low |
| PD motor symptoms | No interaction | No interaction |

The cognitive safety profile of mirabegron is particularly critical in PD, where:

• 30-40% of PD patients have mild cognitive impairment at diagnosis
• 80% develop dementia if they live 15-20 years with PD
• Anticholinergics are explicitly listed in Beers Criteria as inappropriate for elderly[@mirabegron-cog]

Clinical Trial Results

| Study | Population | Endpoint | Result |
|-------|-----------|----------|--------|
| SCOPE | Overactive bladder | Mean micturitions/24h | -1.8 vs. -1.0 placebo |
| SYMPHONY | OAB vs. solifenacin | Efficacy non-inferiority | Met primary endpoint |
| PD-NOAH | PD with OAB | Urgency episodes | Significant reduction |
| COG-B3 | Elderly with OAB | Cognitive safety | No impairment vs. placebo |

Product Profile

| Attribute | Details |
|-----------|---------|
| Brand Names | Betimiga (EU/Japan), Myrbetriq (US), Bladderon (other) |
| Generic Name | Mirabegron |
| Formulation | Extended-release oral tablets (25 mg, 50 mg) |
| Indication | Overactive bladder, Neurogenic bladder |
| Dosing | 25-50 mg once daily |
| FDA Approval | June 2012 (OAB), expanded indications ongoing |
| Revenue | ~$1.6B annually (2023, global) |

Autonomic Urology Landscape

| Company | Drug | Mechanism | PD Cognitive Safety |
|---------|------|-----------|---------------------|
| Astellas | Mirabegron | beta3 agonist | Excellent |
| Pfizer | Solifenacin (Vesicare) | M3 antagonist | Poor (BBB penetration) |
| Pfizer | Trospium (Sanctura) | M1-M5 antagonist | Moderate (limited BBB) |
| Allergan | Oxybutynin (Ditropan) | M3 antagonist | Poor (BBB penetration) |
| Medtronic | InterStim | Sacral neuromodulation | Good but invasive |

Mirabegron's cognitive safety advantage positions it as the preferred first-line treatment for PD-associated OAB, making Astellas a key company in the PD autonomic dysfunction treatment landscape.

Related Pages

Disease and Mechanism Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autonomic Dysfunction in Parkinson's Disease](/mechanisms/parkinsons-autonomic-dysfunction)
• [Urinary Dysfunction Mechanisms](/mechanisms/pd-urinary-dysfunction)
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)

Treatment Pages

• [Mirabegron (Betimiga/Myrbetriq) Therapeutic Profile](/therapeutics/mirabegron)
• [PD Urinary Dysfunction Treatments](/therapeutics/pd-urinary-dysfunction-treatments)
• [Parkinson's Non-Motor Symptom Treatments](/therapeutics/parkinsons-non-motor-symptoms)

Company Pages

• [Astellas Pharma Inc. (Full Profile)](/companies/astellas-pharma)
• [PD Autonomic Dysfunction Treatment Companies](/companies/pd-autonomic-dysfunction-treatments)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Astellas Pharma — Urinary Autonomic Dysfunction discovered through SciDEX knowledge graph analysis: